Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders baseline results from the RAISE-ETP study

JAMA Psychiatry

Volumn 71, Issue 12, 2014, Pages 1350-1363

  Correll, Christoph U ^a,b,c,d   Robinson, Delbert G ^a,b,c,d   Schooler, Nina R ^a,e   Brunette, Mary F ^f,g   Mueser, Kim T ^h,i   Rosenheck, Robert A ^j   Marcy, Patricia ^a,b   Addington, Jean ^k   Estroff, Sue E ^l   Robinson, James ^m   Penn, David L ⁿ   Azrin, Susan ^o   Goldstein, Amy ^o   Severe, Joanne ^o   Heinssen, Robert ^o   Kane, John M ^a,b,c,d  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

^f DARTMOUTH MEDICAL SCHOOL   (United States)

^g Bureau of Behavioral Health Department of Health and Human Services   (Canada)

^h BOSTON UNIVERSITY   (United States)

ⁱ BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j YALE UNIVERSITY   (United States)

^k UNIVERSITY OF CALGARY   (Canada)

^l UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^m NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

ⁿ University of North Carolina at Chapel Hill   (United States)

^o NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ARIPIPRAZOLE; ASENAPINE; ATOMOXETINE; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPNOTIC AGENT; INSULIN; LITHIUM CARBONATE; LITHIUM CITRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LURASIDONE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE; GLUCOSE BLOOD LEVEL; LIPID;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; COMMUNITY MENTAL HEALTH CENTER; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE DURATION; DRUG CHOICE; DYSLIPIDEMIA; ETHNIC DIFFERENCE; FAT MASS; FEMALE; FIRST EPISODE SCHIZOPHRENIA; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PREHYPERTENSION; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SEX DIFFERENCE; SMOKING; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; WAIST CIRCUMFERENCE; ADOLESCENT; BLOOD; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; ETHNIC GROUP; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; PSYCHOSIS; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; BODY COMPOSITION; CARDIOVASCULAR DISEASES; ETHNIC GROUPS; FEMALE; HUMANS; INSULIN; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OVERWEIGHT; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA; SEX FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84915755691     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2014.1314     Document Type: Article

References (79)

1. Laursen TM, Munk-Olsen T, NordentoftM, Mortensen PB. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J Clin Psychiatry. 2007;68(6):899-907
2. Nielsen RE, Uggerby AS, Jensen SO,McGrath JJ. Increasing mortality gap for patients diagnosed with schizophrenia over the last three decades: a Danish nationwide study from 1980 to 2010. Schizophr Res. 2013;146(1-3):22-27
3. Suvisaari J, Partti K, Perl J, et al. Mortality and its determinants in people with psychotic disorder. Psychosom Med. 2013;75(1):60-67
4. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006;3(2): A42
5. Chang CK, Hayes RD, Perera G, et al. Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. PLoS ONE. 2011;6(5):e19590
6. Druss BG, Zhao L, Von Esenwein S, Morrato EH, Marcus SC. Understanding excess mortality in persons with mental illness: 17-year follow up of a nationally representative US survey. Med Care. 2011;49(6):599-604
7. NordentoftM,Wahlbeck K, Hllgren J, et al. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One. 2013;8(1):e55176
8. Osby U, Correia N, Brandt L, Ekbom A, Sparn P. Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ. 2000;321(7259):483-484
9. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123-1131
10. Capasso RM, Lineberry TW, Bostwick JM, Decker PA, St Sauver J. Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950-2005. Schizophr Res. 2008;98(1-3):287-294
11. Hoang U, Stewart R, GoldacreMJ. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006. BMJ. 2011;343:d5422
12. De HertM, Cohen D, Bobes J, et al. Physical illness in patients with severe mental disorders, II: barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.World Psychiatry. 2011;10(2): 138-151
13. DE HertM, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders, I: prevalence, impact of medications and disparities in health care.World Psychiatry. 2011;10(1):52-77
14. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De HertM. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. PsycholMed. 2012;42(1):125-147
15. Mitchell AJ, Lord O. Do deficits in cardiac care influence high mortality rates in schizophrenia? a systematic review and pooled analysis. J Psychopharmacol. 2010;24(4)(suppl):69-80
16. Mitchell AJ, Lord O, Malone D. Differences in the prescribing of medication for physical disorders in individuals with v. without mental illness: meta-analysis. Br J Psychiatry. 2012;201(6):435-443
17. LahtiM, Tiihonen J, Wildgust H, et al. Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia. Psychol Med. 2012;42(11):2275-2285
18. De HertM, Vancampfort D, Correll CU, et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry. 2011;199(2):99-105
19. Tsai KY, Lee CC, Chou YM, Su CY, Chou FH. The incidence and relative risk of stroke in patients with schizophrenia: a five-year follow-up study. Schizophr Res. 2012;138(1):41-47
20. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011;17(2):97-107.
21. DeHert M, Detraux J, vanWinkel R, YuW, Correll CU.Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114-126
22. Srihari VH, Phutane VH, Ozkan B, et al. Cardiovascular mortality in schizophrenia: defining a critical period for prevention. Schizophr Res. 2013; 146(1-3):64-68
23. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765-1773
24. Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry. 2011;68 (6):609-616
25. Ratliff JC, Palmese LB, Reutenauer EL, Srihari VH, Tek C. Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness. Psychosomatics. 2013;54(1):67-73
26. Tirosh A, Shai I, Afek A, et al. Adolescent BMI trajectory and risk of diabetes versus coronary disease. N Engl J Med. 2011;364(14):1315-1325
27. Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry. 2010;71(9):1115-1124
28. Cullen BA, McGinty EE, Zhang Y, et al. Guideline-concordant antipsychotic use and mortality in schizophrenia. Schizophr Bull. 2013;39 (5):1159-1168
29. Tiihonen J, Lnnqvist J,Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620-627
30. Hoang U, GoldacreMJ, Stewart R. Avoidable mortality in people with schizophrenia or bipolar disorder in England. Acta Psychiatr Scand. 2013;127 (3):195-201
31. FirstM, Spitzer R, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition. New York: Biometrics Research, New York State Psychiatric Institute; 1998
32. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrm KO. The Fagerstrm Test for Nicotine Dependence: a revision of the Fagerstrm Tolerance Questionnaire. Br J Addict. 1991;86(9): 1119-1127
33. Correll CU. Monitoring and management of antipsychotic-relatedmetabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry. 2008;20(2):195-201
34. Cook S,Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of ametabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med. 2003;157(8): 821-827
35. Tth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006. J Clin Lipidol. 2012;6(4):325-330
36. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care. 2010;33(suppl 1):S11-S61
37. McLaughlin T, Reaven G, Abbasi F, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol. 2005;96(3):399-404
38. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7): 412-419
39. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19): 2560-2572
40. Grundy SM, Cleeman JI, Daniels SR, et al; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of themetabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112 (17):2735-2752
41. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356-359
42. Centers for Disease Control and Prevention. Vital signs: current cigarette smoking among adults aged18 years with mental illness: United States, 2009-2011. MMWR Morb Mortal Wkly Rep. 2013;62 (5):81-87
43. Keyes KM, Utz RL, RobinsonW, Li G. What is a cohort effect? comparison of three statistical methods for modeling cohort effects in obesity prevalence in the United States, 1971-2006. Soc Sci Med. 2010;70(7):1100-1108
44. Crews DC, Plantinga LC,Miller ER III, et al; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. Prevalence of chronic kidney disease in persons with undiagnosed or prehypertension in the United States. Hypertension. 2010;55(5):1102-1109
45. Heianza Y, Hara S, Arase Y, et al. HbA1c 57-64%and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet. 2011;378(9786):147-155
46. FleischhackerWW, Siu CO, Bodn R, Pappadopulos E, Karayal ON, Kahn RS; EUFEST Study Group.Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. Int J Neuropsychopharmacol. 2013;16(5):987-995
47. Moreno C, Merchn-Naranjo J, Alvarez M, et al. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. Bipolar Disord. 2010;12(2):172-184
48. Perez-Iglesias R, Crespo-Facorro B, Amado JA, et al. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry. 2007; 68(11):1733-1740
49. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25(suppl 2):S12-S21
50. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1050-1060
51. Kinon BJ, Stauffer VL, Kollack-Walker S, Chen L, Sniadecki J. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. J Clin Psychopharmacol. 2008;28 (6):601-607
52. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-nave schizophrenia patients. Neuropsychopharmacology. 2010;35(9):1997-2004
53. Kahn RS, FleischhackerWW, Boter H, et al; EUFEST Study Group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618): 1085-1097
54. Buchanan RW, Kreyenbuhl J, Kelly DL, et al; Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71-93
55. Mitchell AJ, Vancampfort D, De Herdt A, YuW, De HertM. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? a comparativemeta-analysis of first episode, untreated and treated patients. Schizophr Bull. 2013;39(2):295-305
56. McClave AK, McKnight-Eily LR, Davis SP, Dube SR. Smoking characteristics of adults with selected lifetime mental illnesses: results from the 2007 National Health Interview Survey. Am J Public Health. 2010;100(12):2464-2472
57. Manu P, Correll CU,WampersM, et al. Prediabetic increase in hemoglobin A1c compared with impaired fasting glucose in patients receiving antipsychotic drugs. Eur Neuropsychopharmacol. 2013;23(3):205-211
58. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006;86(1-3):15-22
59. Correll CU, Harris JL, Pantaleon Moya RA, Frederickson AM, Kane JM, Manu P. Low-density lipoprotein cholesterol in patients treated with atypical antipsychotics: missed targets and lost opportunities. Schizophr Res. 2007;92(1-3):103-107
60. Correll CU, Druss BG, Lombardo I, et al. Findings of a US national cardiometabolic screening program among 10,084 psychiatric outpatients. Psychiatr Serv. 2010;61(9):892-898
61. Centers for Disease Control and Prevention. Smoking-attributable mortality, years of potential life lost, and productivity losses: United States, 2000-2004. MMWR Morb Mortal Wkly Rep. 2008; 57(45):1226-1228
62. Mucha L, Stephenson J, Morandi N, Dirani R. Meta-analysis of disease risk associated with smoking, by gender and intensity of smoking. Gend Med. 2006;3(4):279-291
63. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004; 328(7455):1519
64. Garrison RJ, Castelli WP.Weight and thirty-year mortality of men in the Framingham Study. Ann Intern Med. 1985;103(6, pt 2):1006-1009
65. Stringhini S, Sabia S, Shipley M, et al. Association of socioeconomic position with health behaviors and mortality. JAMA. 2010;303(12):1159-1166
66. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003;290(1):86-97
67. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. Themetabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163(4):427-436
68. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223
69. Fenelon A. Revisiting the Hispanic mortality advantage in the United States: the role of smoking. Soc Sci Med. 2013;82:1-9
70. DaviglusML, Talavera GA, Avils-SantaML, et al. Prevalence of major cardiovascular risk factors and cardiovascular diseases among Hispanic/Latino individuals of diverse backgrounds in the United States. JAMA. 2012;308(17):1775-1784
71. Yu SS, Castillo DC, Courville AB, Sumner AE. The triglyceride paradox in people of African descent. Metab Syndr Relat Disord. 2012;10(2):77-82
72. Li C, Ford ES, Meng YX, Mokdad AH, Reaven GM. Does the association of the triglyceride to high-density lipoprotein cholesterol ratio with fasting serum insulin differ by race/ethnicity? Cardiovasc Diabetol. 2008;7:4
73. Sumner AE, Zhou J, Doumatey A, et al. Low HDL-cholesterol with normal triglyceride levels is the most common lipid pattern inWest Africans and African Americans with metabolic syndrome: implications for cardiovascular disease prevention. CVD Prev Control. 2010;5(3):75-80
74. Lin SX, Carnethon M, SzkloM, Bertoni A. Racial/ethnic differences in the association of triglycerides with other metabolic syndrome components: the Multi-Ethnic Study of Atherosclerosis. Metab Syndr Relat Disord. 2011;9 (1):35-40
75. Selvin E, SteffesMW, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL. Racial differences in glycemic markers: a cross-sectional analysis of community-based data. Ann Intern Med. 2011;154(5):303-309
76. Sentell TL, He G, Gregg EW, Schillinger D. Racial/ethnic variation in prevalence estimates for United States prediabetes under alternative 2010 American Diabetes Association criteria: 1988-2008. Ethn Dis. 2012;22(4):451-458
77. Ziemer DC, Kolm P,WeintraubWS, et al. Glucose-independent, black-white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies. Ann Intern Med. 2010;152(12):770-777
78. Tsugawa Y, Mukamal KJ, Davis RB, TaylorWC, Wee CC. Should the hemoglobin A1c diagnostic cutoff differ between blacks and whites? a cross-sectional study. Ann Intern Med. 2012;157 (3):153-159
79. Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: ameta-analytic comparison of randomized controlled trials. Schizophr Res. 2012;140(1-3):159-168